- Home
- FRD vs MNOV Comparison
FRD vs MNOV Comparison
Compare FRD & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRD
- MNOV
- Stock Information
- Founded
- FRD 1965
- MNOV 2000
- Country
- FRD United States
- MNOV United States
- Employees
- FRD N/A
- MNOV N/A
- Industry
- FRD Steel/Iron Ore
- MNOV Biotechnology: Pharmaceutical Preparations
- Sector
- FRD Industrials
- MNOV Health Care
- Exchange
- FRD Nasdaq
- MNOV Nasdaq
- Market Cap
- FRD 99.3M
- MNOV 87.3M
- IPO Year
- FRD N/A
- MNOV 2005
- Fundamental
- Price
- FRD $14.61
- MNOV $1.83
- Analyst Decision
- FRD
- MNOV
- Analyst Count
- FRD 0
- MNOV 0
- Target Price
- FRD N/A
- MNOV N/A
- AVG Volume (30 Days)
- FRD 10.3K
- MNOV 136.9K
- Earning Date
- FRD 11-12-2024
- MNOV 11-13-2024
- Dividend Yield
- FRD 1.11%
- MNOV N/A
- EPS Growth
- FRD N/A
- MNOV N/A
- EPS
- FRD 1.14
- MNOV N/A
- Revenue
- FRD $469,515,000.00
- MNOV N/A
- Revenue This Year
- FRD N/A
- MNOV N/A
- Revenue Next Year
- FRD N/A
- MNOV N/A
- P/E Ratio
- FRD $12.74
- MNOV N/A
- Revenue Growth
- FRD N/A
- MNOV N/A
- 52 Week Low
- FRD $11.15
- MNOV $1.12
- 52 Week High
- FRD $19.52
- MNOV $2.55
- Technical
- Relative Strength Index (RSI)
- FRD 49.69
- MNOV 52.22
- Support Level
- FRD $13.85
- MNOV $1.49
- Resistance Level
- FRD $14.72
- MNOV $2.55
- Average True Range (ATR)
- FRD 0.61
- MNOV 0.18
- MACD
- FRD 0.06
- MNOV 0.03
- Stochastic Oscillator
- FRD 35.35
- MNOV 36.84
About FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.